| Across Specialties |
| Cardiovascular Disease |
| Child & Adolescent Medicine |
| Conference News |
| Diabetes, Endocrinology & Metabolism |
| Infectious Diseases |
| Podcasts |
| Practice Trends |
| Video Library |
| RSS Feed |
| About Family Practice News Digital Network |
| Editorial Staff |
| Editorial Advisory Board |
| Contact Us |
| Advertise |
| Subscription Renew |
| Privacy Policy |
| Copyright & Terms of Use |
By: JEFF EVANS, Family Practice News Digital Network
Two different approaches to treating spinocerebellar ataxia type 1 – aerobic exercise or delivery of vascular endothelial growth factor – appeared to halt or slow the dysfunction of vulnerable cerebellar and brain stem cells in separate studies of a mouse model that closely mirrors the human disease.
The studies also shed light on how the poly-glutamine repeat mutation found in the AXTN1 gene of patients with spinocerebellar ataxia type 1 (SCA1) affects the transcription of particular genes that may contribute to the disease’s hallmark pathology of atrophy and loss of Purkinje neurons from the cerebellar cortex.
Patients with SCA1 most often initially experience problems with gait and balance, followed later by other motor difficulties, cognitive impairment, and sometimes sensory neuropathy, dystonia, and muscle atrophy and fasciculations.
Exercise Increased Life Span
The researchers, led by John D. Fryer, Ph.D., at Baylor College of Medicine, Houston, found that a regimen of relatively light exercise 5 days per week at an early age extended the life of mice with SCA1 by up to 6 weeks but did not improve their motor performance. This exercise led to a sustained increase in the level of epidermal growth factor (EGF) in the brain stem but not in the cerebellum (Science 2011;334:690-3).
The investigators also looked at how exercise affected the function of a transcriptional repressor protein called Capicua (Cic) that interacts with the ATXN1 gene’s protein product (ataxin 1) and lies downstream of EGF signaling.
Levels of Cic in SCA1 mice declined in the brainstem but not in the cerebellum after the exercise training period. Similarly, when brainstem neuronal cultures from SCA1 mice were exposed to EGF, levels of Cic declined. This suggested that a reduction of Cic itself might improve the survival of the SCA1 mice.
Further experiments showed that genetically reducing the level of Cic by 50% in SCA1 mice significantly improved their motor coordination, learning, and memory deficits; curbed the loss of Purkinje cells at 40 weeks of age; and extended their life span.
Genetic reduction of Cic improved motor coordination, according to Dr. Fryer and his coauthors. However, exercise on its own or in the amount undertaken in the first group of SCA1 mice did not improve motor coordination, judging from the observation that it lowered Cic levels only in the brainstem rather than in the cerebellum.
The investigators suggested that the deleterious effects of mutant ataxin 1 may be moderated by lower levels of Cic because the mutant protein appeared to cause a simultaneous increase or decrease in Cic’s transcriptional repression of certain genes. Based on these results, the researchers thought that therapeutics aimed at lowering Cic levels or disrupting the interaction between Cic and mutant ataxin 1 "could potentially ameliorate the disease."
Because the effect of exercise on life span lasted long after the mice stopped exercising, they suggested that "SCA1 individuals might benefit from an exercise program early in disease course." They described the exercise regimen as being "quite gentle," so they could not rule out "the possibility that more intense or longer-duration exercise could cause a sustained EGF increase and Cic decrease in the cerebellum that could lead to motor improvements."




